TNF and psoriasis vulgaris: Of the biologic therapies, interleukin (IL) inhibitors were more commonly prescribed in patients with GPP than in those with plaque psoriasis (13.6% vs 0.6%, respectively), as were TNF inhibitors (10.9% vs 0.9%, respectively) (Figure 4).